Stockscreener 앱 받기
2.10
2.44%
0.05
시간 외 거래:
2.08
-0.02
-0.95%
전일 마감가:
$2.05
열려 있는:
$2.06
하루 거래량:
1.08M
Relative Volume:
0.77
시가총액:
$402.71M
수익:
-
순이익/손실:
$-54.70M
주가수익비율:
-6.3636
EPS:
-0.33
순현금흐름:
$-51.36M
1주 성능:
-4.11%
1개월 성능:
-12.50%
6개월 성능:
-31.60%
1년 성능:
-51.16%
1일 변동 폭
$2.03
$2.14
1주일 범위
$1.98
$2.29
52주 변동 폭
$1.89
$5.11
사바라 Stock (SVRA) Company Profile
명칭
Savara Inc
전화
51285113796
주소
6836 BEE CAVE ROAD, AUSTIN, TX
SVRA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SVRA
Savara Inc
|
2.10 | 402.71M | 0 | -54.70M | -51.36M | -0.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
사바라 Stock (SVRA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-29 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-12-20 | 개시 | Wells Fargo | Overweight |
| 2024-11-13 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-02-15 | 개시 | JMP Securities | Mkt Outperform |
| 2023-11-07 | 개시 | Guggenheim | Buy |
| 2023-05-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-03-31 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-03-16 | 개시 | Piper Sandler | Overweight |
| 2021-03-15 | 개시 | Oppenheimer | Outperform |
| 2019-06-13 | 재확인 | H.C. Wainwright | Buy |
| 2019-06-13 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-13 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2018-08-13 | 재개 | ROTH Capital | Neutral |
| 2018-01-03 | 개시 | Ladenburg Thalmann | Buy |
| 2017-09-27 | 재개 | ROTH Capital | Buy |
| 2017-09-22 | 개시 | Jefferies | Buy |
| 2017-09-11 | 개시 | JMP Securities | Mkt Outperform |
모두보기
사바라 주식(SVRA)의 최신 뉴스
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc.SVRA - Bluefield Daily Telegraph
Insiders Who Purchased US$783.7k Of Savara Stock May Not Have Expected 12% Tumble - simplywall.st
Savara’s SWOT analysis: biotech firm’s stock poised for growth with aPAP drug - Investing.com
Savara Inc (NASDAQ:SVRA) Stake Reduced by California State Teachers Retirement System - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $482,000 Stock Holdings in Savara Inc (NASDAQ:SVRA) - Defense World
Savara Inc (NASDAQ:SVRA) Shares Sold by Bank of America Corp DE - Defense World
Ameriprise Financial Inc. Takes Position in Savara Inc (NASDAQ:SVRA) - Defense World
Jane Street Group LLC Decreases Stock Holdings in Savara Inc (NASDAQ:SVRA) - Defense World
savara elects board members and approves proposals at annual meeting - Investing.com Australia
savara elects board members and approves proposals at annual meeting By Investing.com - Investing.com South Africa
Savara Re-elects Board Members at Annual Meeting - TipRanks
Savara Inc (NASDAQ:SVRA) Shares Bought by Squarepoint Ops LLC - Defense World
FDA Requests Additional Data for Savara’s MOLBREEVI Application - MSN
Savara assumed with an Outperform at Oppenheimer - MSN
Nuveen Asset Management LLC Sells 30,766 Shares of Savara Inc (NASDAQ:SVRA) - Defense World
Savara Inc. to Present at Jefferies Global Healthcare Conference on June 4, 2025 - MSN
Millennium Management LLC Grows Stake in Savara Inc (NASDAQ:SVRA) - Defense World
Savara Inc (NASDAQ:SVRA) Shares Bought by ProShare Advisors LLC - Defense World
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Savara Inc.SVRA - FinancialContent
Insider Buying Alert: Joseph Mccracken Acquires Additional Shares of Savara Inc (SVRA) - GuruFocus
Oppenheimer assumes Savara stock at outperform, sets $5 price target - Investing.com
Oppenheimer assumes Savara stock at outperform, sets $5 price target By Investing.com - Investing.com Canada
Oppenheimer Adjusts Price Target on Savara to $5 From $15, Maintains Outperform Rating - marketscreener.com
Oppenheimer Maintains Optimism for Savara (SVRA) Despite Filing Setback | SVRA Stock News - GuruFocus
Savara director Joseph McCracken buys $20,825 in stock By Investing.com - Investing.com South Africa
Savara director Joseph McCracken buys $20,825 in stock - Investing.com Australia
What is HC Wainwright’s Forecast for Savara FY2026 Earnings? - Defense World
Savara Inc (NASDAQ:SVRA) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
What is HC Wainwright’s Forecast for Savara FY2029 Earnings? - Defense World
Savara Inc. Grants Equity Awards to New Employees - MSN
FDA Denies Langhorne-Based Savara Application for Rare Lung Disease Treatment - BUCKSCO.Today
Did Savara Inc. (SVRA) Mislead Investors? Levi & Korsinsky Investigates - ACCESS Newswire
Savara (NASDAQ:SVRA) Lowered to “Neutral” Rating by HC Wainwright - Defense World
SVRA: Savara Downgraded by HC Wainwright & Co. | SVRA Stock News - GuruFocus
Savara stock rating cut to Neutral by H.C. Wainwright - Investing.com Nigeria
HC Wainwright & Co. Downgrades Savara (SVRA) - MSN
This Starbucks Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday - Benzinga
HC Wainwright Downgrades Savara to Neutral From Buy, Adjusts Price Target to $2 From $6 - marketscreener.com
H.C. Wainwright Lowers Savara (SVRA) Outlook Following FDA Setba - GuruFocus
H.C. Wainwright Lowers Savara (SVRA) Outlook Following FDA Setback | SVRA Stock News - GuruFocus
Savara stock price target cut to $2 at Evercore ISI By Investing.com - Investing.com Canada
Savara Inc (NASDAQ:SVRA) Shares Bought by D. E. Shaw & Co. Inc. - Defense World
Guggenheim Reaffirms “Buy” Rating for Savara (NASDAQ:SVRA) - Defense World
Savara (NASDAQ:SVRA) Given New $2.00 Price Target at Evercore ISI - Defense World
Savara (NASDAQ:SVRA) Price Target Lowered to $7.00 at Wells Fargo & Company - Defense World
SVRA ALERT: Levi & Korsinsky Investigates Savara Inc. on Behalf of Shareholders Who Lost Money - ACCESS Newswire
Savara Showcases Promising Phase 3 Trial Data for Molgramostim at ATS 2025 - MSN
사바라 (SVRA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
사바라 주식 (SVRA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| McCracken Joseph S | Director |
May 29 '25 |
Buy |
2.08 |
10,000 |
20,825 |
260,837 |
| RAMSAY DAVID A | Director |
Mar 31 '25 |
Buy |
2.77 |
150,000 |
416,250 |
2,513,642 |
| Lowrance David L | Chief Financial Officer |
Dec 16 '24 |
Sale |
3.33 |
25,000 |
83,278 |
381,005 |
| Pauls Matthew | CHIEF EXECUTIVE OFFICER |
Dec 16 '24 |
Sale |
3.31 |
54,702 |
180,828 |
1,536,379 |
| Hawkins Richard J | Director |
Dec 16 '24 |
Sale |
3.32 |
8,000 |
26,569 |
67,241 |
1.45%
0.86%
자본화:
|
볼륨(24시간):